- Home
- DAC vs LBPH Comparison
DAC vs LBPH Comparison
Compare DAC & LBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAC
- LBPH
- Stock Information
- Founded
- DAC 1972
- LBPH 2020
- Country
- DAC Greece
- LBPH United States
- Employees
- DAC N/A
- LBPH 33
- Industry
- DAC Marine Transportation
- LBPH Biotechnology: Pharmaceutical Preparations
- Sector
- DAC Consumer Discretionary
- LBPH Health Care
- Exchange
- DAC Nasdaq
- LBPH Nasdaq
- Market Cap
- DAC 1.6B
- LBPH 2.3B
- IPO Year
- DAC 2006
- LBPH 2021
- Fundamental
- Price
- DAC $85.80
- LBPH $59.80
- Analyst Decision
- DAC Strong Buy
- LBPH Buy
- Analyst Count
- DAC 1
- LBPH 8
- Target Price
- DAC $105.00
- LBPH $52.29
- AVG Volume (30 Days)
- DAC 112.4K
- LBPH 858.5K
- Earning Date
- DAC 11-12-2024
- LBPH 11-07-2024
- Dividend Yield
- DAC 3.73%
- LBPH N/A
- EPS Growth
- DAC 0.27
- LBPH N/A
- EPS
- DAC 28.90
- LBPH N/A
- Revenue
- DAC $1,005,246,000.00
- LBPH N/A
- Revenue This Year
- DAC $4.87
- LBPH N/A
- Revenue Next Year
- DAC N/A
- LBPH N/A
- P/E Ratio
- DAC $2.93
- LBPH N/A
- Revenue Growth
- DAC 2.92
- LBPH N/A
- 52 Week Low
- DAC $66.45
- LBPH $3.60
- 52 Week High
- DAC $98.25
- LBPH $59.95
- Technical
- Relative Strength Index (RSI)
- DAC 57.26
- LBPH 78.93
- Support Level
- DAC $83.02
- LBPH $59.47
- Resistance Level
- DAC $87.47
- LBPH $59.85
- Average True Range (ATR)
- DAC 2.17
- LBPH 0.15
- MACD
- DAC 0.30
- LBPH -0.81
- Stochastic Oscillator
- DAC 60.66
- LBPH 76.92
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.